Johnson & Johnson’s second quarter sales rose, but its orthopedic segment sales saw a less than 1% decrease, according to financial results posted July 16.
Five things to know:
1. Global orthopedic sales of $2.3 billion, falling 0.3% short compared to the same period in 2024.
2. Hip sales of $421 million represent a 1% increase year over year, and knee sales of $389 million is a 1.1% decrease.
3. Spine, sports and other sales decreased 2.1% year over year with $727 million. Trauma sales increased 1.2% in the second quarter with $768 million.
4. The dip in orthopedic sales was due to “competitive pressures, the transformation program, and China volume-based procurement,” Johnson & Johnson CFO Darren Snellgrove, said in a quarterly earnings call.
5. Johnson & Johnson’s total second quarter sales grew 5.8% year over year with $23.7 billion.
